The Dual Syk/Jak Inhibitor Cerdulatinib Demonstrates Rapid Tumor Responses In A Phase 2 Study In Patients With Relapsed/Refractory B- And T-Cell Non-Hodgkin Lymphoma (Nhl).Paul A. Hamlin,Bruce D. Cheson,Charles M. Farber,Tatyana Feldman,Timothy S. Fenske,Brian T. Hess,James Khatcheressian,Carole B. Miller,Javier Munoz,Manish R. Patel,Sonali M. Smith,Stephen D. Smith,Don A. Stevens,Jing Christine Ye,Andrew Steele,Anjali Pandey,Matt Birrell,Janet Leeds,Greg Coffey,John T. CurnutteJOURNAL OF CLINICAL ONCOLOGY（2018）引用 9|浏览58暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
